Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Semler Scientific, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Semler Scientific securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Disclosure and Market Reaction - Semler Scientific filed its 2024 annual report on Form 10-K with the SEC, revealing that it had begun initial settlement discussions with the DOJ but ceased those discussions on February 11, 2025 [3]. - Following this disclosure, Semler Scientific's stock fell over 9% on the next trading day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed competition impacts on the company's primary product [3][5]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical and its executives made false or misleading statements regarding the demand for their primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competitive pressures affecting revenue [5]. - Following a press release on May 7, 2024, the company lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million, indicating significant revenue decline [6]. - The stock price of Treace Medical fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, following the announcement of the lowered revenue guidance [7]. Group 2: Legal Proceedings - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal rights and options, with a deadline of June 10, 2025, to seek the role of lead plaintiff in the federal securities class action [2][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Treace's conduct [9].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NeuroPace, Inc. and its officers or directors [1] Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3] - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3] - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of NeuroPace to gather information regarding potential claims related to securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a class action lawsuit due to significant stock price decline following disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses [2][3]. Group 1: Company Performance - On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, citing Contract Manufacturing headwinds and the loss of two major continuous glucose monitoring customers [2]. - The company's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the need for steps to improve its economics [2]. - Following the announcement, West's stock price fell by $123.17, or 38.2%, closing at $199.11 per share [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that West made materially false and misleading statements throughout the class period, failing to disclose significant operational issues [3]. - Specific allegations include ongoing destocking across West's high-margin HVP portfolio and operational inefficiencies related to the SmartDose device, which was expected to be a high-margin growth product [3]. - The lawsuit claims that these margin pressures could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3].

Core Insights - Intuitive Surgical is transitioning from being solely recognized for its da Vinci robotic-assisted surgery system to becoming a comprehensive surgical platform company that integrates hardware, software, and AI [1] Group 1: Company Evolution - The company is evolving into a surgical platform that combines various technologies, indicating a shift towards a more integrated approach in the healthcare sector [1] - Intuitive Surgical's Nebula Fund is focused on investing in transformative opportunities across technology and emerging industries, showcasing the company's commitment to innovation [1] Group 2: Investment Strategy - The Nebula Fund employs a data-driven investment strategy aimed at identifying and accelerating advancements in sectors such as AI, quantum computing, clean energy, fintech, and next-generation infrastructure [1] - The insights provided by the Nebula Fund are based on rigorous analysis and macro trend forecasting, which aims to equip investors with actionable intelligence [1]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Treace Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the ...

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the June 10, 2025 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the Class Period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]

Core Insights - Medtronic has faced significant challenges in recent years, including a pandemic-induced slowdown and slow revenue growth, but its diabetes care business has been a fast-growing segment [1][2] - The company announced plans to spin off its diabetes care segment into a stand-alone, publicly traded corporation within the next 18 months to simplify its portfolio and focus on high-margin growth opportunities [8] Diabetes Care Segment - Medtronic's diabetes care segment includes products like insulin pumps, continuous glucose monitoring (CGM) systems, insulin pens, and software for tracking patient progress [3][4] - The diabetes care segment generated $2.8 billion in sales during fiscal 2025, reflecting a year-over-year growth of 10.7%, although it still represents a small part of the overall business [6][7] Market Opportunities - There is significant growth potential in the diabetes market, with only 1% of the half-billion adults with diabetes having access to CGM technology as of the end of 2023 [4] - Medtronic's decision to spin off the diabetes care unit may stem from challenges in competing with leaders like Abbott Laboratories and DexCom in the CGM market and Tandem Diabetes Care in the insulin pump niche [9] Overall Business Outlook - Despite losing its fastest-growing segment, Medtronic's overall business remains robust, with a diverse range of products generating consistent revenue and profits [10] - The company is also pursuing U.S. clearance for its Hugo robotic-assisted surgery system, which could unlock significant growth opportunities in the underpenetrated surgical market [11] Dividend and Long-term Performance - Medtronic has a strong track record as a dividend stock, having increased its dividends for 48 consecutive years, positioning it as a potential Dividend King [12] - The company has performed relatively well in the current year compared to broader equity markets and is expected to mitigate the impact of tariffs due to its diversified business model [13]

NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2025 lead plaintiff deadline.So what: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...